US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MBX Biosciences

66.39

+0.06000.09%

Volume:531.07K

Turnover:35.23M

Market Cap:3.20B

PE:-27.60

High:67.16

Open:66.23

Low:64.00

Close:66.33

52wk High:72.64

52wk Low:9.63

Shares:48.16M

Float Shares:27.63M

Volume Ratio:1.07

T/O Rate:1.92%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.4052

EPS(LYR):-2.3824

ROE:-33.17%

ROA:-22.08%

PB:7.81

PE(LYR):-27.87

Loading ...

Overview Company News Filings

MBX Biosciences Inc. publishes corporate presentation on endocrine and metabolic peptide drug development pipeline

Earnings Flash (MBX) MBX Biosciences Posts Q4 Net Loss $0.49 a Share, vs. FactSet Est of $0.63 Loss

MT Newswires Live

MBX Biosciences Q4 EPS $(0.49) Beats $(0.68) Estimate

Benzinga Earnings

MBX Biosciences FY 2025 net loss rose 40% to USD 86.97 million, while G&A expenses jumped 75% to USD 18.9 million

Press Release: MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights

Mbx Biosciences Appoints Karen Basbaum as Chief Business Officer

THOMSON REUTERS

Press Release: MBX Biosciences Appoints Karen Basbaum as Chief Business Officer

Microbix Advances Modernized Manufacturing for Kinlytic Clot-Buster Drug

MBX Biosciences plans Q3 2026 Phase 3 trial for once-weekly canvuparatide in hypoparathyroidism

Mbx Biosciences Inc - to Initiate Phase 3 Trial for Canvuparatide in Q3 2026

THOMSON REUTERS

MBX Biosciences Says CFO to Step Down; Names Interim Finance Chief

MT Newswires Live

MBX Biosciences Announces CFO Transition and Interim Appointment

Microbix Issues New Stock Options to Retain Senior Talent and Manage Dilution

Evaluating MBX Biosciences (MBX) Valuation After MBX 2109 Phase 2 Progress And Stronger Investor Sentiment

Simply Wall St.

MBX Biosciences to Participate in March Investor Conferences in Miami

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/MBX/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MBX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","market":"US","secType":"STK","nameCN":"MBX Biosciences","latestPrice":66.39,"timestamp":1787601600000,"preClose":66.33,"halted":0,"volume":531065,"delay":0,"changeRate":0.0009045680687472075,"floatShares":27629899,"shares":48160096,"eps":-2.4052,"marketStatus":"Not Yet Opened","change":0.06,"latestTime":"08-24 16:00:00 EDT","open":66.23,"high":67.155,"low":64,"amount":35228664.1122,"amplitude":0.047565,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.4052,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":0,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":66.33,"postHourTrading":{"tag":"盘后","latestPrice":66.39,"preClose":66.39,"latestTime":"19:30 EDT","volume":27453,"amount":1822607.07,"timestamp":1787614203482,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.073547,"impliedVol":0.9162,"impliedVolPercentile":0.436},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","floatShares":27629899,"roa":"-22.08%","roe":"-33.17%","lyrEps":-2.382369,"volumeRatio":1.073547,"shares":48160096,"dividePrice":0,"high":67.155,"amplitude":0.047565,"preClose":66.33,"low":64,"week52Low":9.63,"pbRate":"7.81","week52High":72.64,"institutionHeld":0,"latestPrice":66.39,"eps":-2.4052,"divideRate":0,"volume":531065,"delay":0,"ttmEps":-2.4052,"open":66.23,"prevYearClose":31.54,"prevWeekClose":66.33,"prevMonthClose":65.93,"prevQuarterClose":55.2,"fiveDayClose":68.25,"twentyDayClose":61.3,"sixtyDayClose":31.9},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MBX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"MBX","fiscalQuarterEnding":"2026/06","expectedEps":-0.68,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.78},{"market":"US","date":"2026-05-07","symbol":"MBX","fiscalQuarterEnding":"2026/03","expectedEps":-0.62,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-0.51},{"market":"US","date":"2026-03-12","symbol":"MBX","fiscalQuarterEnding":"2025/12","expectedEps":-0.64,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773288000000,"reportTimeType":"pre","actualEps":-0.49},{"market":"US","date":"2025-11-06","symbol":"MBX","fiscalQuarterEnding":"2025/09","expectedEps":-0.73,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.63},{"market":"US","date":"2025-08-07","symbol":"MBX","fiscalQuarterEnding":"2025/06","expectedEps":-0.77,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.58}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MBX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MBX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":12,"updateTime":1787544000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MBX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MBX","date":"2026-08-21","current":-27.602694,"percent":0.063786,"low":-38.854907,"twenty":-18.368939,"median":-13.111638,"eighty":-5.710784,"high":-3.125337,"avg":-13.512388,"sd":8.053337,"marketCap":3195422369},"quantilePoints":[{"date":"2024-09-13","current":-15.960592,"twenty":-13.895501,"median":-10.797864,"eighty":-10.797864,"marketCap":753339957},{"date":"2024-09-20","current":-15.949203,"twenty":-15.694582,"median":-15.111074,"eighty":-12.419885,"marketCap":752802389},{"date":"2024-09-27","current":-16.939398,"twenty":-16.33255,"median":-15.751164,"eighty":-14.917986,"marketCap":799539567},{"date":"2024-10-04","current":-16.797941,"twenty":-16.986079,"median":-16.110499,"eighty":-15.091977,"marketCap":792862827},{"date":"2024-10-11","current":-16.932325,"twenty":-16.986079,"median":-16.31699,"eighty":-15.248994,"marketCap":799205730},{"date":"2024-10-18","current":-17.024271,"twenty":-17.032759,"median":-16.518565,"eighty":-15.369232,"marketCap":803545610},{"date":"2024-10-25","current":-15.022664,"twenty":-17.021442,"median":-16.380645,"eighty":-15.369232,"marketCap":709069745},{"date":"2024-11-01","current":-15.885548,"twenty":-16.991737,"median":-16.362963,"eighty":-15.369232,"marketCap":749797857},{"date":"2024-11-08","current":-13.874718,"twenty":-16.947885,"median":-16.309917,"eighty":-15.248994,"marketCap":765593046},{"date":"2024-11-15","current":-10.66494,"twenty":-16.936569,"median":-16.143706,"eighty":-14.480386,"marketCap":588480730},{"date":"2024-11-22","current":-11.203941,"twenty":-16.918179,"median":-15.949203,"eighty":-13.805677,"marketCap":618222233},{"date":"2024-11-29","current":-12.318278,"twenty":-16.877157,"median":-15.751164,"eighty":-12.380051,"marketCap":679710282},{"date":"2024-12-06","current":-13.432616,"twenty":-16.771064,"median":-15.461179,"eighty":-11.837418,"marketCap":741198331},{"date":"2024-12-13","current":-11.470413,"twenty":-16.663558,"median":-15.31265,"eighty":-11.837418,"marketCap":632925896},{"date":"2024-12-20","current":-12.330391,"twenty":-16.662143,"median":-15.019127,"eighty":-11.803503,"marketCap":680378630},{"date":"2024-12-27","current":-12.154761,"twenty":-16.656485,"median":-14.542475,"eighty":-11.803503,"marketCap":670687579},{"date":"2025-01-03","current":-11.258446,"twenty":-16.435813,"median":-14.054537,"eighty":-11.676323,"marketCap":621229800},{"date":"2025-01-10","current":-8.290916,"twenty":-16.380645,"median":-13.850493,"eighty":-11.492215,"marketCap":457484452},{"date":"2025-01-17","current":-5.989566,"twenty":-16.372157,"median":-13.75965,"eighty":-11.117943,"marketCap":330498264},{"date":"2025-01-24","current":-6.510398,"twenty":-16.36367,"median":-13.256987,"eighty":-10.797864,"marketCap":359237243},{"date":"2025-01-31","current":-6.06224,"twenty":-16.342452,"median":-12.878476,"eighty":-9.893382,"marketCap":334508354},{"date":"2025-02-07","current":-7.473331,"twenty":-16.314161,"median":-12.457571,"eighty":-8.809325,"marketCap":412370938},{"date":"2025-02-14","current":-6.304488,"twenty":-16.290113,"median":-12.324334,"eighty":-7.444262,"marketCap":347875321},{"date":"2025-02-21","current":-6.589128,"twenty":-16.247676,"median":-12.215323,"eighty":-7.171733,"marketCap":363581507},{"date":"2025-02-28","current":-5.813937,"twenty":-16.175534,"median":-12.009413,"eighty":-6.798672,"marketCap":320807212},{"date":"2025-03-07","current":-5.989566,"twenty":-16.064646,"median":-11.803503,"eighty":-6.591551,"marketCap":330498264},{"date":"2025-03-14","current":-5.26888,"twenty":-15.958314,"median":-11.682379,"eighty":-6.514032,"marketCap":290731536},{"date":"2025-03-21","current":-4.258879,"twenty":-15.936472,"median":-11.549143,"eighty":-6.294798,"marketCap":263718287},{"date":"2025-03-28","current":-4.188707,"twenty":-15.858671,"median":-11.258446,"eighty":-6.213645,"marketCap":259373118},{"date":"2025-04-04","current":-3.260282,"twenty":-15.749749,"median":-11.107042,"eighty":-6.057395,"marketCap":201883200},{"date":"2025-04-11","current":-3.999783,"twenty":-15.687509,"median":-10.797864,"eighty":-5.922948,"marketCap":247674589},{"date":"2025-04-17","current":-4.113138,"twenty":-15.461179,"median":-10.66494,"eighty":-5.686757,"marketCap":254693707},{"date":"2025-04-25","current":-4.949799,"twenty":-15.461179,"median":-9.901861,"eighty":-5.438453,"marketCap":306501482},{"date":"2025-05-02","current":-6.477382,"twenty":-15.454106,"median":-9.653557,"eighty":-5.327647,"marketCap":401092452},{"date":"2025-05-09","current":-5.996976,"twenty":-15.31265,"median":-8.539219,"eighty":-5.438453,"marketCap":371344761},{"date":"2025-05-16","current":-5.077465,"twenty":-15.206557,"median":-7.473331,"eighty":-5.077465,"marketCap":373015980},{"date":"2025-05-23","current":-5.691675,"twenty":-15.022664,"median":-7.246225,"eighty":-5.226487,"marketCap":418138881},{"date":"2025-05-30","current":-5.787218,"twenty":-15.017006,"median":-7.134185,"eighty":-5.260401,"marketCap":425157999},{"date":"2025-06-06","current":-5.395944,"twenty":-14.885451,"median":-6.813207,"eighty":-5.315894,"marketCap":396413040},{"date":"2025-06-13","current":-4.877278,"twenty":-14.35621,"median":-6.707223,"eighty":-5.172099,"marketCap":358309257},{"date":"2025-06-20","current":-4.677092,"twenty":-14.130289,"median":-6.595185,"eighty":-5.059804,"marketCap":343602533},{"date":"2025-06-27","current":-5.136611,"twenty":-14.052953,"median":-6.564904,"eighty":-5.017962,"marketCap":377361148},{"date":"2025-07-03","current":-5.673476,"twenty":-13.977856,"median":-6.515167,"eighty":-5.013234,"marketCap":416801906},{"date":"2025-07-11","current":-5.641628,"twenty":-13.855338,"median":-6.4303,"eighty":-5.035235,"marketCap":414462200},{"date":"2025-07-18","current":-5.548359,"twenty":-13.804466,"median":-6.320845,"eighty":-5.055522,"marketCap":407610204},{"date":"2025-07-25","current":-5.928259,"twenty":-13.766918,"median":-6.298431,"eighty":-5.072006,"marketCap":435519554},{"date":"2025-08-01","current":-6.028352,"twenty":-13.628836,"median":-6.310434,"eighty":-5.101123,"marketCap":442872915},{"date":"2025-08-08","current":-4.830149,"twenty":-13.362364,"median":-6.283291,"eighty":-5.101123,"marketCap":372013249},{"date":"2025-08-15","current":-5.76189,"twenty":-13.198847,"median":-6.22399,"eighty":-5.101123,"marketCap":443774969},{"date":"2025-08-22","current":-6.171895,"twenty":-13.089836,"median":-6.221845,"eighty":-5.14935,"marketCap":475353203},{"date":"2025-08-29","current":-6.224236,"twenty":-12.914207,"median":-6.224236,"eighty":-5.170279,"marketCap":479384467},{"date":"2025-09-05","current":-5.635398,"twenty":-12.685283,"median":-6.241684,"eighty":-5.176649,"marketCap":434032748},{"date":"2025-09-12","current":-4.331231,"twenty":-12.593229,"median":-6.221845,"eighty":-5.070186,"marketCap":333587089},{"date":"2025-09-19","current":-4.392296,"twenty":-12.449092,"median":-6.213645,"eighty":-5.008506,"marketCap":338290230},{"date":"2025-09-26","current":-10.057984,"twenty":-12.39822,"median":-6.217295,"eighty":-5.008506,"marketCap":774655869},{"date":"2025-10-03","current":-9.721364,"twenty":-12.327968,"median":-6.224236,"eighty":-5.029502,"marketCap":748729706},{"date":"2025-10-10","current":-9.207959,"twenty":-12.309799,"median":-6.253122,"eighty":-5.039662,"marketCap":709187798},{"date":"2025-10-17","current":-7.994552,"twenty":-12.25166,"median":-6.280939,"eighty":-5.051241,"marketCap":615732407},{"date":"2025-10-24","current":-9.364715,"twenty":-12.13417,"median":-6.307461,"eighty":-5.070186,"marketCap":721260982},{"date":"2025-10-31","current":-12.650784,"twenty":-12.13417,"median":-6.352937,"eighty":-5.089294,"marketCap":974350701},{"date":"2025-11-07","current":-13.743232,"twenty":-12.309799,"median":-6.369154,"eighty":-5.142981,"marketCap":1106261420},{"date":"2025-11-14","current":-13.426901,"twenty":-12.512852,"median":-6.477382,"eighty":-5.169369,"marketCap":1080798409},{"date":"2025-11-21","current":-15.07807,"twenty":-12.739549,"median":-6.521866,"eighty":-5.176649,"marketCap":1213709223},{"date":"2025-11-28","current":-19.239461,"twenty":-13.256987,"median":-6.567932,"eighty":-5.191208,"marketCap":1548680395},{"date":"2025-12-05","current":-17.036043,"twenty":-13.72255,"median":-6.589128,"eighty":-5.211681,"marketCap":1371316303},{"date":"2025-12-12","current":-15.859028,"twenty":-13.826268,"median":-6.619611,"eighty":-5.226487,"marketCap":1276572445},{"date":"2025-12-19","current":-15.992906,"twenty":-14.046615,"median":-6.70403,"eighty":-5.26888,"marketCap":1287348998},{"date":"2025-12-26","current":-17.911832,"twenty":-14.268105,"median":-6.806351,"eighty":-5.279538,"marketCap":1441812917},{"date":"2026-01-02","current":-17.59387,"twenty":-14.917986,"median":-6.813207,"eighty":-5.295223,"marketCap":1416218605},{"date":"2026-01-09","current":-17.136452,"twenty":-15.146199,"median":-7.076651,"eighty":-5.307262,"marketCap":1379398717},{"date":"2026-01-16","current":-22.820712,"twenty":-15.452731,"median":-7.200803,"eighty":-5.317689,"marketCap":1836953174},{"date":"2026-01-23","current":-23.646296,"twenty":-15.472295,"median":-7.424882,"eighty":-5.324948,"marketCap":1903408581},{"date":"2026-01-30","current":-20.550355,"twenty":-15.847871,"median":-7.61062,"eighty":-5.334947,"marketCap":1654200805},{"date":"2026-02-06","current":-20.109671,"twenty":-15.97998,"median":-7.994552,"eighty":-5.365916,"marketCap":1618727987},{"date":"2026-02-13","current":-22.260078,"twenty":-16.085028,"median":-8.265761,"eighty":-5.405044,"marketCap":1791824944},{"date":"2026-02-20","current":-21.826592,"twenty":-16.300015,"median":-8.354645,"eighty":-5.422333,"marketCap":1756931510},{"date":"2026-02-27","current":-20.526135,"twenty":-16.365085,"median":-8.65641,"eighty":-5.437203,"marketCap":1652251211},{"date":"2026-03-06","current":-18.414356,"twenty":-16.656674,"median":-8.777334,"eighty":-5.439664,"marketCap":1482263608},{"date":"2026-03-13","current":-15.268438,"twenty":-16.663558,"median":-8.888641,"eighty":-5.448143,"marketCap":1327911291},{"date":"2026-03-20","current":-15.530651,"twenty":-16.662191,"median":-9.207959,"eighty":-5.4632,"marketCap":1350716208},{"date":"2026-03-27","current":-15.454172,"twenty":-16.656674,"median":-9.44019,"eighty":-5.477809,"marketCap":1344064774},{"date":"2026-04-02","current":-17.639279,"twenty":-16.656721,"median":-9.686541,"eighty":-5.527885,"marketCap":1534105746},{"date":"2026-04-10","current":-17.950657,"twenty":-16.797941,"median":-9.847355,"eighty":-5.527885,"marketCap":1561186584},{"date":"2026-04-17","current":-18.147317,"twenty":-16.939398,"median":-9.944254,"eighty":-5.546084,"marketCap":1578290272},{"date":"2026-04-24","current":-18.240184,"twenty":-16.993812,"median":-10.091627,"eighty":-5.548359,"marketCap":1586367013},{"date":"2026-05-01","current":-16.529418,"twenty":-17.017199,"median":-10.162452,"eighty":-5.565633,"marketCap":1437580056},{"date":"2026-05-08","current":-19.051466,"twenty":-17.024271,"median":-10.419594,"eighty":-5.573382,"marketCap":1651171534},{"date":"2026-05-15","current":-19.432949,"twenty":-17.098465,"median":-10.797864,"eighty":-5.623429,"marketCap":1683048872},{"date":"2026-05-22","current":-17.470969,"twenty":-17.116218,"median":-10.949581,"eighty":-5.635398,"marketCap":1513125669},{"date":"2026-05-29","current":-17.531422,"twenty":-17.244113,"median":-11.182744,"eighty":-5.640382,"marketCap":1518361398},{"date":"2026-06-05","current":-16.987343,"twenty":-17.244113,"median":-11.332873,"eighty":-5.647113,"marketCap":1471239837},{"date":"2026-06-12","current":-20.471645,"twenty":-17.244113,"median":-11.549143,"eighty":-5.650278,"marketCap":1773008216},{"date":"2026-06-18","current":-22.856798,"twenty":-17.305607,"median":-11.667238,"eighty":-5.653457,"marketCap":1979581522},{"date":"2026-06-26","current":-27.68206,"twenty":-17.435508,"median":-11.803503,"eighty":-5.659497,"marketCap":2397487888},{"date":"2026-07-02","current":-30.732198,"twenty":-17.480357,"median":-11.965702,"eighty":-5.666777,"marketCap":2661654213},{"date":"2026-07-10","current":-36.112531,"twenty":-17.527026,"median":-11.991245,"eighty":-5.673476,"marketCap":3127634090},{"date":"2026-07-17","current":-32.051177,"twenty":-17.634503,"median":-12.154761,"eighty":-5.678788,"marketCap":2775888299},{"date":"2026-07-24","current":-34.936442,"twenty":-17.867538,"median":-12.324334,"eighty":-5.688724,"marketCap":3025775363},{"date":"2026-07-31","current":-36.524712,"twenty":-17.911832,"median":-12.436374,"eighty":-5.691675,"marketCap":3163332242},{"date":"2026-08-07","current":-30.628146,"twenty":-17.994359,"median":-12.627144,"eighty":-5.692585,"marketCap":3194270640},{"date":"2026-08-14","current":-30.97629,"twenty":-18.158049,"median":-12.72465,"eighty":-5.698044,"marketCap":3230579239},{"date":"2026-08-21","current":-30.63919,"twenty":-18.368939,"median":-13.111638,"eighty":-5.710784,"marketCap":3195422369}],"updateTime":1787644750369},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MBX\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618134286","title":"MBX Biosciences Inc. publishes corporate presentation on endocrine and metabolic peptide drug development pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2618134286","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618134286?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:29","pubTimestamp":1773318572,"startTime":"0","endTime":"0","summary":"MBX said it had USD 459.1 million in pro forma cash and investments as of Dec. 31, 2025, and stated this provides runway into 2029. The company said it expects an Avail Phase 2 presentation with one-year open-label extension data for canvuparatide  in Q2 2026 and plans to initiate a Phase 3 trial in Q3 2026. MBX said Phase 1 12-week multiple ascending dose results for MBX 4291 are anticipated in Q4 2026. The company also said it plans to nominate a development candidate for MBX 5XXX in Q2 2026 and for MBX 6XXX in Q3 2026. MBX said results from the STEADI Phase 2a trial of imapextide  are anticipated in Q2 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDLbnskQt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618663134","title":"Earnings Flash (MBX) MBX Biosciences Posts Q4 Net Loss $0.49 a Share, vs. FactSet Est of $0.63 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2618663134","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618663134?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:16","pubTimestamp":1773317772,"startTime":"0","endTime":"0","summary":"Earnings Flash (MBX) MBX Biosciences Posts Q4 Net Loss $0.49 a Share, vs. FactSet Est of $0.63 Loss","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618134353","title":"MBX Biosciences Q4 EPS $(0.49) Beats $(0.68) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618134353","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618134353?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:14","pubTimestamp":1773317640,"startTime":"0","endTime":"0","summary":"MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.68) by 27.84 percent. This is a 4.26 percent decrease over losses of $(0.47) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51209331/mbx-biosciences-q4-eps-0-49-beats-0-68-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618131001","title":"MBX Biosciences FY 2025 net loss rose 40% to USD 86.97 million, while G&A expenses jumped 75% to USD 18.9 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131001","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131001?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:05","pubTimestamp":1773317106,"startTime":"0","endTime":"0","summary":"MBX Biosciences reported a Q4 net loss of USD 22.06 million, up 42% year over year. Q4 R&D expense rose 30% to USD 19.76 million, driven by costs for the MBX 4291 Phase 1 trial, the canvuparatide Phase 2 Avail trial and Phase 3 preparation activities. Q4 G&A expense increased 78% to USD 6.04 million, reflecting higher personnel-related costs and professional fees as a public company. For FY 2025, net loss widened 40% to USD 86.97 million, while R&D expense increased 38% to USD 79.16 million. MBX said pro forma cash and investments were USD 459.1 million as of Dec. 31, 2025, including USD 85.4 million of net proceeds raised through its ATM facility, and expects this to fund operations into 2029.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDL3sjqbM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4112","BK4588","LU2210149790.SGD","MBX","IE00BKPKM429.USD","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014021.USD","IE00B64PRP62.GBP","LU2095319765.USD","BK4585","SG9999014013.SGD","LU0314104364.USD","NDAQ","SG9999014039.USD","BK4007","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618213178","title":"Press Release: MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2618213178","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618213178?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:00","pubTimestamp":1773316800,"startTime":"0","endTime":"0","summary":"Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA. 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026. Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026. $459.1 million in pro forma cash and investments as of December 31, 2025, including $85.4 million in net proceeds from top-tier institutional investors through ATM program; expected to support operations into 2029. \"2025 was a year of continued growth and execution for MBX, highlighted by the clinical validation of our Precision Endocrine Peptide  platform,\" said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. \"Following a successful End-of-Phase 2 meeting with the FDA, we now have a clear path to initiate our Phase 3 trial of once-weekly canvuparatide. We are also advancing a growing obesity p","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4099","03160","BK4604","BK4555","HP","PBH","MBX","TM","BK4092","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618937058","title":"Mbx Biosciences Appoints Karen Basbaum as Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2618937058","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618937058?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:00","pubTimestamp":1773144008,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUABM80XR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618693702","title":"Press Release: MBX Biosciences Appoints Karen Basbaum as Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2618693702","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618693702?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:00","pubTimestamp":1773144000,"startTime":"0","endTime":"0","summary":"CARMEL, Ind., March 10, 2026  -- MBX Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Karen Basbaum, MBA, as Chief Business Officer . Ms. Basbaum brings more than two decades of leadership in corporate strategy, business development, and strategic transactions across the biotechnology and pharmaceutical industries.\"Karen is a highly accomplished and strategic leader with a proven track record of sourcing, structuring, and executing high-value partnerships, financings, and mergers and acquisitions that create long-term shareholder value,\" said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. \"Her experience executing complex, value-creating agreements with major global pharmaceutical companies will be instrumental as we advance our pipeline and pursue strategic opp","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","BK4007","HP","BK4099","MBX","BK4585","BK4588","PBH","BK4604","03160","BK4092","BK4555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618930338","title":"Microbix Advances Modernized Manufacturing for Kinlytic Clot-Buster Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2618930338","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618930338?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:51","pubTimestamp":1773143506,"startTime":"0","endTime":"0","summary":"Microbix Biosystms ( ($TSE:MBX) ) just unveiled an announcement. Microbix Biosystems and its U.S. commercialization partner Sequel Pharma have adva...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-advances-modernized-manufacturing-for-kinlytic-clot-buster-drug?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-advances-modernized-manufacturing-for-kinlytic-clot-buster-drug?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618625631","title":"MBX Biosciences plans Q3 2026 Phase 3 trial for once-weekly canvuparatide in hypoparathyroidism","url":"https://stock-news.laohu8.com/highlight/detail?id=2618625631","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618625631?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:04","pubTimestamp":1773057844,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDL4hXwNM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618623009","title":"Mbx Biosciences Inc - to Initiate Phase 3 Trial for Canvuparatide in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2618623009","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618623009?lang=en_us&edition=fundamental","pubTime":"2026-03-09 20:00","pubTimestamp":1773057601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA2GBQS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614851263","title":"MBX Biosciences Says CFO to Step Down; Names Interim Finance Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2614851263","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614851263?lang=en_us&edition=fundamental","pubTime":"2026-02-27 22:08","pubTimestamp":1772201314,"startTime":"0","endTime":"0","summary":"MBX Biosciences  said Friday that Chief Financial Officer Richard Bartram will step down, effective March 15, and that John Smither has been named interim CFO.The company said in a regulatory filing that Bartram will serve as a consultant to the company following his resignation and that it has begun a search for a new CFO.MBX said Bartram's departure is not related to any disagreement with the company or its auditors.Smither is a former CFO of Arcutis Biotherapeutics  and is currently a member of the boards of NewAmsterdam Pharma  and Genelux Corporation .Shares of MBX Biosciences were 1.3% lower in recent premarket trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4007","NAMS","MBX","GNLX","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614854306","title":"MBX Biosciences Announces CFO Transition and Interim Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2614854306","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614854306?lang=en_us&edition=fundamental","pubTime":"2026-02-27 22:05","pubTimestamp":1772201130,"startTime":"0","endTime":"0","summary":"MBX Biosciences, Inc. ( ($MBX) ) has provided an update. On February 24, 2026, MBX Biosciences, Inc. signed a lease with 5 Burlington Woods, LLC fo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-announces-cfo-transition-and-interim-appointment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-announces-cfo-transition-and-interim-appointment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613717844","title":"Microbix Issues New Stock Options to Retain Senior Talent and Manage Dilution","url":"https://stock-news.laohu8.com/highlight/detail?id=2613717844","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613717844?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:54","pubTimestamp":1771941295,"startTime":"0","endTime":"0","summary":"Microbix Biosystms ( ($TSE:MBX) ) just unveiled an update. Microbix Biosystems has granted 2,600,000 stock options under its shareholder-approved s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-issues-new-stock-options-to-retain-senior-talent-and-manage-dilution?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-issues-new-stock-options-to-retain-senior-talent-and-manage-dilution?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MBX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613765920","title":"Evaluating MBX Biosciences (MBX) Valuation After MBX 2109 Phase 2 Progress And Stronger Investor Sentiment","url":"https://stock-news.laohu8.com/highlight/detail?id=2613765920","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613765920?lang=en_us&edition=fundamental","pubTime":"2026-02-24 11:25","pubTimestamp":1771903509,"startTime":"0","endTime":"0","summary":"MBX Biosciences (MBX) is drawing attention after progress updates on its lead therapy MBX 2109 in Phase 2 trials for chronic hypoparathyroidism and early pipeline candidates in other metabolic indications, along with stronger recent investor interest.\nSee our latest analysis for MBX Biosciences.\nAt a recent share price of $36.75, MBX Biosciences has paired a 5.63% 1 day share price return and 16.30% 90 day share price return with a 1 year total shareholder return of about 3.5x. This suggests...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/evaluating-mbx-biosciences-mbx-valuation-after-mbx-2109-phas","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/evaluating-mbx-biosciences-mbx-valuation-after-mbx-2109-phas","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MBX","BK4007","PRGS","BK4097","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613752784","title":"MBX Biosciences to Participate in March Investor Conferences in Miami","url":"https://stock-news.laohu8.com/highlight/detail?id=2613752784","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613752784?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:00","pubTimestamp":1771851635,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on February 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL6Q8XXL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00B64PRP62.GBP","LU2210149790.SGD","LU2095319765.USD","LU0314104364.USD","IE00BKPKM429.USD","BK4585","LU2210150020.SGD","BK4007","MBX","IE00BGHQF748.EUR","NDAQ","SG9999014005.SGD","SG9999014013.SGD","BK4588","SG9999014021.USD","IE00B3QW5Z07.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":115,"code":"91000000","status":"200"}]}}